FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997026783> ?p ?o ?g. }

• W1997026783 endingPage "5606" @default.
• W1997026783 startingPage "5600" @default.
• W1997026783 abstract "Nilotinib has significant efficacy in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and in patients with CML-CP or CML in accelerated phase (CML-AP) after imatinib failure. We investigated the occurrence of cross-intolerance to nilotinib in imatinib-intolerant patients with CML. Only 1/75 (1%) patients with nonhematologic imatinib intolerance experienced a similar grade 3/4 adverse event (AE), and 3/75 (4%) experienced a similar persistent grade 2 nonhematologic AE on nilotinib. Only 7/40 (18%) patients with hematologic imatinib intolerance discontinued nilotinib, all because of grade 3/4 thrombocytopenia. Ninety percent of imatinib-intolerant patients with CML-CP who did not have complete hematologic response (CHR) at baseline (n = 52) achieved CHR on nilotinib. Nilotinib induced a major cytogenetic response in 66% and 41% of patients with imatinib-intolerant CML-CP and CML-AP (complete cytogenetic response in 51% and 30%), respectively. Minimal cross-intolerance was confirmed in patients with imatinib-intolerant CML. The favorable tolerability of nilotinib in patients with imatinib intolerance leads to alleviation of AE-related symptoms and significant and durable responses. In addition to its established clinical benefit in patients with newly diagnosed CML and those resistant to imatinib, nilotinib is effective and well-tolerated for long-term use in patients with imatinib intolerance. This study is registered at http://www.clinicaltrials.gov as NCT00471497." @default.
• W1997026783 created "2016-06-24" @default.
• W1997026783 creator A5000192349 @default.
• W1997026783 creator A5009003698 @default.
• W1997026783 creator A5015140142 @default.
• W1997026783 creator A5028793559 @default.
• W1997026783 creator A5035964802 @default.
• W1997026783 creator A5044224344 @default.
• W1997026783 creator A5049385583 @default.
• W1997026783 creator A5052899201 @default.
• W1997026783 creator A5060360947 @default.
• W1997026783 creator A5061285204 @default.
• W1997026783 creator A5067073779 @default.
• W1997026783 creator A5090435894 @default.
• W1997026783 date "2011-05-26" @default.
• W1997026783 modified "2023-10-17" @default.
• W1997026783 title "Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib" @default.
• W1997026783 cites W1488234136 @default.
• W1997026783 cites W1965429870 @default.
• W1997026783 cites W2006917576 @default.
• W1997026783 cites W2013850642 @default.
• W1997026783 cites W2020103507 @default.
• W1997026783 cites W2028959752 @default.
• W1997026783 cites W2034862875 @default.
• W1997026783 cites W2052202516 @default.
• W1997026783 cites W2057718276 @default.
• W1997026783 cites W2058677025 @default.
• W1997026783 cites W2066099870 @default.
• W1997026783 cites W2068133101 @default.
• W1997026783 cites W2072483737 @default.
• W1997026783 cites W2084133200 @default.
• W1997026783 cites W2134566943 @default.
• W1997026783 cites W2137063143 @default.
• W1997026783 cites W2143939343 @default.
• W1997026783 cites W2158933399 @default.
• W1997026783 doi "https://doi.org/10.1182/blood-2010-11-318949" @default.
• W1997026783 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4186645" @default.
• W1997026783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21467546" @default.
• W1997026783 hasPublicationYear "2011" @default.
• W1997026783 type Work @default.
• W1997026783 sameAs 1997026783 @default.
• W1997026783 citedByCount "54" @default.
• W1997026783 countsByYear W19970267832012 @default.
• W1997026783 countsByYear W19970267832013 @default.
• W1997026783 countsByYear W19970267832014 @default.
• W1997026783 countsByYear W19970267832015 @default.
• W1997026783 countsByYear W19970267832016 @default.
• W1997026783 countsByYear W19970267832017 @default.
• W1997026783 countsByYear W19970267832018 @default.
• W1997026783 countsByYear W19970267832019 @default.
• W1997026783 countsByYear W19970267832020 @default.
• W1997026783 countsByYear W19970267832021 @default.
• W1997026783 countsByYear W19970267832022 @default.
• W1997026783 countsByYear W19970267832023 @default.
• W1997026783 crossrefType "journal-article" @default.
• W1997026783 hasAuthorship W1997026783A5000192349 @default.
• W1997026783 hasAuthorship W1997026783A5009003698 @default.
• W1997026783 hasAuthorship W1997026783A5015140142 @default.
• W1997026783 hasAuthorship W1997026783A5028793559 @default.
• W1997026783 hasAuthorship W1997026783A5035964802 @default.
• W1997026783 hasAuthorship W1997026783A5044224344 @default.
• W1997026783 hasAuthorship W1997026783A5049385583 @default.
• W1997026783 hasAuthorship W1997026783A5052899201 @default.
• W1997026783 hasAuthorship W1997026783A5060360947 @default.
• W1997026783 hasAuthorship W1997026783A5061285204 @default.
• W1997026783 hasAuthorship W1997026783A5067073779 @default.
• W1997026783 hasAuthorship W1997026783A5090435894 @default.
• W1997026783 hasBestOaLocation W19970267831 @default.
• W1997026783 hasConcept C126322002 @default.
• W1997026783 hasConcept C197934379 @default.
• W1997026783 hasConcept C2777413986 @default.
• W1997026783 hasConcept C2777583451 @default.
• W1997026783 hasConcept C2778375690 @default.
• W1997026783 hasConcept C2778729363 @default.
• W1997026783 hasConcept C3019892230 @default.
• W1997026783 hasConcept C71924100 @default.
• W1997026783 hasConcept C90924648 @default.
• W1997026783 hasConceptScore W1997026783C126322002 @default.
• W1997026783 hasConceptScore W1997026783C197934379 @default.
• W1997026783 hasConceptScore W1997026783C2777413986 @default.
• W1997026783 hasConceptScore W1997026783C2777583451 @default.
• W1997026783 hasConceptScore W1997026783C2778375690 @default.
• W1997026783 hasConceptScore W1997026783C2778729363 @default.
• W1997026783 hasConceptScore W1997026783C3019892230 @default.
• W1997026783 hasConceptScore W1997026783C71924100 @default.
• W1997026783 hasConceptScore W1997026783C90924648 @default.
• W1997026783 hasIssue "21" @default.
• W1997026783 hasLocation W19970267831 @default.
• W1997026783 hasLocation W19970267832 @default.
• W1997026783 hasLocation W19970267833 @default.
• W1997026783 hasLocation W19970267834 @default.
• W1997026783 hasOpenAccess W1997026783 @default.
• W1997026783 hasPrimaryLocation W19970267831 @default.
• W1997026783 hasRelatedWork W1510497893 @default.
• W1997026783 hasRelatedWork W1974941790 @default.
• W1997026783 hasRelatedWork W1991773845 @default.
• W1997026783 hasRelatedWork W2051726599 @default.
• W1997026783 hasRelatedWork W2073935113 @default.

• next